Genentech Files Against Novo Nordisk On Insulin
Genentech of the USA has filed an amended complaint alleging that Novo Nordisk infringes five Genentech patents in the manufacture and sale of NN's recombinant human insulin product, Novolin in the USA.
Stephen Raines, Genentech's vice president for intellectual property, said: "Novo Nordisk has already acknowledged in court Genentech's significant contribution to the development of recombinant human insulin."
NN said that it believes that Genentech's assertions are totally unfounded and completely without merit. The company said: "it is our position that the production and distribution of our human recombinant DNA-origin insulin products does not infringe any Genentech patents. We intend to vigorously fight these baseless accusations."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze